News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I mean you cannot make this ish up. HILARIOUS. Its called MASSIVE DILUTION. Ichim knows this.
https://stocktwits.com/Stock85/message/572307554
You need a certain amount of shareholders to go public and a mkt cap. Raymond oliver has a great back round you might want to check it out.
Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2854789
0.00057 50,000,000 avg @ 11:32:58
T/A Verified Responsible Party to be as only one signature on the discounted shares paperwork Timothy G. Dixon
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/trades
Guess some don't much believe in the value of those damn dividends since the 1st pump; offering has being supposedly withdrawn & then refiled / remarketed again @ a discount to previous 
will you look at that..MASSIVE DILUTION!
Cents range?! That is a serious down grade!
A mere half a year ago or so, you were telling the board that CNSI shares might reach $10? Wouldn't a company that owns a sub worth 150M plus have a MC higher than one of its many subs? You know something along the lines of the $20 you were predicting.
It might be a better time to get in now, but I still think if someone did buy because of my post, it will still do them good. Two of the products I've taken has surely helped me. I hope it took you a long time looking through my posts. In time I'll be doing the same to many people on this board. It's only a matter of time. Bio's take time.
Thanks again.
Thanks for saying that little johnny.
Time will tell
Unrestricted OS 2,941,814,475 04/22/2024
https://www.otcmarkets.com/stock/TSOI/security
8's are a bargain here imo, anything under 8's is not being confirmed by weekly stochastics, and this ticker's a classic OTC runner!
8K Out: IT IS RESOLVED, that it is in the best interest of the Company and its shareholders to refile the corporate action as soon as practicable to offer a loyalty dividend to TSOI shareholders in the form of up to Ten Million (10,000,000) shares of Campbell Neurosciences, Inc. (“CNSI”) beneficially owned by TSOI by issuing a prorated loyalty dividend to TSOI shareholders in CNSI at a ratio of 0.0022 shares of CNSI stock for each one (1) share owned in TSOI stock (10,000,000/4,458,184,291 = 0.002243065640016) as of April 30, 2024 (the “Dividend Offer”) on the record date of the action of May 15, 2024 (“Dividend Offer Date”), the Dividend Offer to remain open for Ninety (90) days from the Dividend Offer Date (on or about August 14, 2024), the initial corporate action filed on or about 3/27/2023 being withdrawn on or about 3/12/2024 principally due to staleness.
https://www.otcmarkets.com/filing/html?id=17511475&guid=1YQ-k6dE6TGaJth
|
Followers
|
524
|
Posters
|
|
|
Posts (Today)
|
5
|
Posts (Total)
|
65778
|
|
Created
|
10/04/08
|
Type
|
Free
|
| Moderators BigBadWolf johnnytrader33 JMC$ Yooperman Hogwarts | |||
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress. In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage. Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells.
"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent. "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."
"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."
"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus."
"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans. We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."
1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.
AI
